Global Psoriasis Drugs Market - Segmented by Type of Treatment, by Mechanism of Action, and by Route of Administration - Growth, Trends, and Forecast (2022 - 2030)
The psoriasis drugs market is expected to witness a CAGR of 9.3% during the forecast period. North America dominates the global market due to the high healthcare infrastructure, high adoption of therapeutics, and presence of major players in that region.
Increasing Use of Combination Therapies
A newer treatment approach that is being used is to combine two types of systemic drugs, i.e., a traditional drug and a biologic. More research is still continuing on this approach, however, studies conducted suggest that it often eases psoriasis symptoms more effectively than either treatment by itself. Biologics usually take a while to work. Combining a biologic with a faster-acting systemic drug, such as cyclosporine, is usually much more effective and safe. With faster, longer-lasting results and fewer side effects, requiring lower doses, many doctors are prescribing combination therapies, which is expected to drive the psoriasis drugs market.
Additionally, increasing disease burden and demand for psoriasis medicines in emerging economies and increase in psoriasis research and pipeline drugs are also driving the global psoriasis drugs market.
Adverse Side Effects of Existing Medications
Biologic drugs that target specific proteins or cells, are typically prescribed when other treatments have failed. Common side effects range from minor injection-site reactions to flu-like symptoms, to more serious respiratory infections. Biologic medication might also lead to an increased risk for infection or cancer of the lymph nodes (lymphoma), and they may also be associated with heart failure or central nervous system disorders. As a result of these side effects, these drugs are not prescribed for a long period of time. Many patients are also apprehensive to take drugs with potential adverse side effects, which is a major factor restraining the global psoriasis drugs market.
Additionally, the high cost of psoriasis treatments, extensive drug development, and approval process are hindering the growth of global psoriasis drugs market.
North America is Dominating the Market
North America dominates the global market due to the high healthcare infrastructure, high adoption of therapeutics, and presence of major players in that region. Moreover, increasing prevalence and favorable government initiatives are some of the drivers that are responsible for the growth of the market.
Key Developments in the Market
• August 2017: Boehringer Ingelheim Pharmaceuticals Inc. got approval for Cyltezo for the treatment of multiple chronic inflammatory diseases, including active psoriatic arthritis, moderate to severe active adult Crohn’s disease, and moderate to severe plaque psoriasis.
Major Players: ELI LILLY, PFIZER INC., JANSSEN BIOTECH, INC., CELGENE CORPORATION, TAKEDA PHARMACEUTICAL COMPANY LIMITED, STIEFEL LABORATORIES INC., NOVARTIS AG, AMGEN INC., BIOGEN IDEC, and ABBVIE INC amongst others.
Reasons to Purchase the Report
• Current and future market outlook for psoriasis drugs in the developed and emerging markets
• Analyze various perspectives of the market, with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth, during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players.
• 3-month analyst support, along with the market estimate sheet in excel.
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Increasing Use of Combination Therapies
A newer treatment approach that is being used is to combine two types of systemic drugs, i.e., a traditional drug and a biologic. More research is still continuing on this approach, however, studies conducted suggest that it often eases psoriasis symptoms more effectively than either treatment by itself. Biologics usually take a while to work. Combining a biologic with a faster-acting systemic drug, such as cyclosporine, is usually much more effective and safe. With faster, longer-lasting results and fewer side effects, requiring lower doses, many doctors are prescribing combination therapies, which is expected to drive the psoriasis drugs market.
Additionally, increasing disease burden and demand for psoriasis medicines in emerging economies and increase in psoriasis research and pipeline drugs are also driving the global psoriasis drugs market.
Adverse Side Effects of Existing Medications
Biologic drugs that target specific proteins or cells, are typically prescribed when other treatments have failed. Common side effects range from minor injection-site reactions to flu-like symptoms, to more serious respiratory infections. Biologic medication might also lead to an increased risk for infection or cancer of the lymph nodes (lymphoma), and they may also be associated with heart failure or central nervous system disorders. As a result of these side effects, these drugs are not prescribed for a long period of time. Many patients are also apprehensive to take drugs with potential adverse side effects, which is a major factor restraining the global psoriasis drugs market.
Additionally, the high cost of psoriasis treatments, extensive drug development, and approval process are hindering the growth of global psoriasis drugs market.
North America is Dominating the Market
North America dominates the global market due to the high healthcare infrastructure, high adoption of therapeutics, and presence of major players in that region. Moreover, increasing prevalence and favorable government initiatives are some of the drivers that are responsible for the growth of the market.
Key Developments in the Market
• August 2017: Boehringer Ingelheim Pharmaceuticals Inc. got approval for Cyltezo for the treatment of multiple chronic inflammatory diseases, including active psoriatic arthritis, moderate to severe active adult Crohn’s disease, and moderate to severe plaque psoriasis.
Major Players: ELI LILLY, PFIZER INC., JANSSEN BIOTECH, INC., CELGENE CORPORATION, TAKEDA PHARMACEUTICAL COMPANY LIMITED, STIEFEL LABORATORIES INC., NOVARTIS AG, AMGEN INC., BIOGEN IDEC, and ABBVIE INC amongst others.
Reasons to Purchase the Report
• Current and future market outlook for psoriasis drugs in the developed and emerging markets
• Analyze various perspectives of the market, with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth, during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players.
• 3-month analyst support, along with the market estimate sheet in excel.
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
